| Detailed information |
|---|
| CancerLivER ID | 2178 |
| Biomarker | miR-122 |
| Biomarker Name/Symbol (given in Publication) | miR-122 |
| Biomolecule | miRNA |
| Subject | Human |
| Degree of Validity | miR-122 as a diagnostic and prognostic marker for HCC progression and validated on independent dataset |
| Experimental Condition | Normal vs HCC; associated with survival, tumor size and differentiation status |
| Cancer type | Hepatocellular carcinoma |
| Regulation | variable expression between different hepatoma cell lines: PLC/PRF/5, Huh-1, and Hep40 exhibited very high levels of miR-122, whereas others, such as Hep3B and HepG2, expressed little or did not express miR-122 at all (e.g. SNU387, and SNU398) ; in HCC patients miR-122 was specifically repressed in |
| Level of significance | p < 0.001 |
| Source | Tissue and Cells |
| PMID | 19617899 |
| Type of Biomarker | Diagnostic and Prognostic |
| Pathway | cancer related pathway, Ingenuity pathway |
| Cohort | 64 HCC tissues and 28 matched nontumor surrounding liver tissues were obtained from patients and 21 HCC cell lines i.e. PLC, PRF, Hep40, Huh-6, Huh-1, HLF, HepG2, Hep3B, FOCUS, THLE-2, THLE-3, HEL, SNU387 and SNU398 etc. |
| Sensitivity | NA |
| Specificity | NA |
| Accuracy | NA |
| AUC | NA |
| Disease | Human HCC |
| Year of Publication | 2009 |
| Clinical trial | YES |
| NCT No# (Clinical trial) | NCT03039062 |